Tigecycline: first of a new class of antimicrobial agents (Q28253736)

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

Europe PubMed Central

title

Tigecycline: first of a new class of antimicrobial agents (English)

0 references

2

Michael J Rybak

0 references

author name string

Warren E Rose

series ordinal

1

0 references

language of work or name

English

0 references

publication date

August 2006

0 references

published in

Pharmacotherapy

0 references

volume

26

0 references

issue

8

0 references

page(s)

1099-110

0 references

cites work

1 reference

https://api.crossref.org/works/10.1592/PHCO.26.8.1099

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

20 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.26.8.1099

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

20 April 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Staphylococcus aureus with reduced susceptibility to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Pharmacodynamic effects of subinhibitory antibiotic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1099

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.8.1099

1 reference

Consolidated OpenCitations Corpus – April 2017

330295

330295

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference